Bristol-Myers Q2 Sales Fall, Will Focus on Cancer Drugs

Now watching

Next video starts in : 7 Play

Bristol-Myers Q2 Sales Fall, Will Focus on Cancer Drugs

Bristol-Myers Q2 Sales Fall, Will Focus on Cancer Drugs
Replay video
Up next

What to Watch Friday: Consumer Income, Spending, & Sentiment

Unlock your personal NFL Now stream by signing in to NFL.com

Bristol-Myers Q2 Sales Fall, Will Focus on Cancer Drugs

by TheStreet 0:49 mins

Bristol-Myers Q2 Sales Fall, Will Focus on Cancer Drugs

by TheStreet 0:49 mins

Bristol-Myers Squibb's murky earnings report reveals a company still in flux. Earnings were slightly above analyst estimates at 48 cents a share. The company's revenue came in at $3.9 billion, down 4% from the same quarter last year. The sales decline is a result of the company selling its stake in a diabetes alliance with AstraZeneca. The company's CEO said, "During the second quarter we delivered strong financial and operating results, invested in key business development opportunities, and achieved important regulatory milestones..." Bristol-Myers is hopeful of winning regulatory approval for its new immunotherapy treatment in the next year as the company looks to narrow its focus on cancer drugs. TheStreet’s Julie Cerullo reports from New York.

TheStreet

Finance

  1. 1:01

    The Biebs is back: Justin Bieber by the numbers

  2. 1:04

    Yahoo Finance cocktail of the week: The wild ride

  3. 14:54

    Markets calm down, Sprint vs. AT&T and 'sky high' wifi prices

  4. 4:23

    China fears linger as focus on Fed sharpens

  5. 3:34

    China's Wanda buys Ironman Triathlon owner for $650 mln

  6. 2:31

    Sky high wifi prices

Personal Finance

  1. 3:44

    A local man’s view on the real recovery of post-Katrina New Orleans

  2. A local man’s view on the real recovery of post-Katrina New Orleans

  3. 1:40

    How Much Money Do You Need to Be Rich? Kids' Answers Will Inspire You.

  4. 1:34

    Young people and startups are fueling New Orleans’ recovery after Hurricane Katrina

  5. 1:52

    Here's how smart investors will react to today's market drama

  6. 2:33

    In post-Katrina New Orleans, black men lift each other up

Investing

  1. 1:39

    Icahn buys into FCX, big changes at BIG, ULTA looking pretty

  2. 1:52

    Three tests face a market shaken by volatility storm

  3. 1:31

    3 tips for managing money in a volatile market

  4. 3:52

    Analyst trolls Chanos, says he's lying about Elon Musk's SolarCIty

  5. 3:47

    Unhinged market tests Wall Street rules of thumb

  6. 5:03

    No fundamental reason for oil's 'meltdown': energy analyst

Market Movers